Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes
The Journal of Clinical Endocrinology & Metabolism · 2025
DOI: 10.1210/clinem/dgae817 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Jillian Fetzner und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Diabetes and Metabolic Care Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Cardiovascular Diseases, Body Weight. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 73 Literaturangaben.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Context
The incidence of diabetes is growing at an alarming rate globally. Most of these projected individuals will develop type 2 diabetes (T2DM), raising their risk of cardiovascular disease and chronic kidney disease. This mini-review examines current noninsulin and noninjectable pharmacotherapy focused in T2DM, highlighting the effect on glycemic control and importance of cardiovascular and renal outcomes. Evidence acquisition We included population level data and searched the PubMed database for recent systematic reviews, meta-analyses, and original research articles. Evidence synthesis There is a pharmacologic menu of noninsulin-based medications for the treatment of diabetes. Through varying mechanisms, all agents ultimately lead to glycemic improvement to varying degrees. Only a select number of agents are shown to improve important clinical cardiovascular and renal outcomes. Of note, sodium-glucose cotransporter-2 inhibitors have improved cardiovascular mortality and time to dialysis in people with diabetes. Likewise, incretin-based therapies have improved important cardiovascular and renal composite outcomes in those with diabetes and cardiovascular disease. As a result, agents with proven cardiovascular and renal benefits should be prioritized based on patient risk.
Conclusion
Despite the availability of new medications and technology, published clinical guidelines, and treatment algorithms, most people with diabetes remain above glycemic targets. We encourage clinicians to follow the guidelines and use appropriate medications to lower cardiovascular risk, delay progression of chronic kidney disease, reach glycemic targets, and manage weight.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine, Diabetes and Metabolic Care Center, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA.
ORCID-Profile: Jillian Fetzner, Ebne Rafi
Zitieren
APA
Fetzner, J., & Rafi, E. (2025). Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae817
Vancouver
Fetzner J, Rafi E. Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae817
BibTeX
@article{Fetzner2025,
author = {Fetzner, Jillian and Rafi, Ebne},
title = {Glycemic, Cardiorenal, and Weight Implications on Noninsulin Pharmacotherapy for the Management of Type 2 Diabetes},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2025},
doi = {10.1210/clinem/dgae817}
}
EUVIMED